TAGLN2 and neoplasm: Through the results of tumor weight, it was found that TAGLN2-overexpressing group exhibited higher tolerance to Cisplatin treatment than NC group (33.7% vs 57.7%), and the inhibitory ability of MK2206 treatment alone was similar (19.6% vs 18.2%).